Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels

Loading news article.

Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels | WAPE

Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels

Article summary

Related companies

Comments —